SOURCE: Levi & Korsinsky, LLP
NEW YORK, NY--(Marketwired - Aug 14, 2014) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Regado Biosciences, Inc. ("Regado" or the "Company") (NASDAQ: RGDO) securities pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in relation to the Initial Public Offering on or about August 21, 2013, or on the open market between August 22, 2013 and July 2, 2014.
For more information, click here: http://zlk.9nl.com/regado-biosciences-rgdo.
The complaint alleges that during the Class Period defendants failed to disclose that the danger and frequency of allergic reactions experienced by subjects in the REG1 Phase 3 trial were significant enough to derail the trial, and that the allergic reactions were so serious in nature and/or frequency as to likely result in a hold on the trial.
If you suffered a loss in Regado you have until September 30, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/regado-biosciences-rgdo.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington, D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.